Talk:ABCC2

From Libre Pathology

Revision as of 00:30, 19 May 2026 by Michael (talk | contribs) (→‎Abstract: new section)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Abstract

Papillary renal cell carcinoma with ABCC2 brush border immunoreactivity confers resistance to cabozantinib, highlighting the therapeutic potential of ABCC2 inhibition - CKCis 2026

Retrieved from "https://librepathology.org/w/index.php?title=Talk:ABCC2&oldid=53787"